<DOC>
	<DOCNO>NCT01263899</DOCNO>
	<brief_summary>This Phase 2 study ass efficacy SB1518 treatment patient advance lymphoid malignancy include Hodgkin Lymphoma , Mantle Cell Lymphoma Indolent Lymphoma ( follicular lymphoma , lymphoplasmacytic lymphoma , marginal zone lymphoma small lymphocytic lymphoma ) .</brief_summary>
	<brief_title>A Safety Efficacy Study SB1518 Treatment Advanced Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>Patients histologically document diagnosis one follow lymphoid malignancy : Hodgkin Lymphoma ; Mantle Cell Lymphoma ; Indolent Lymphoma ( include follicular lymphoma , lymphoplasmacytic lymphoma , marginal zone lymphoma small lymphocytic lymphoma ) ; Patients must receive least one prior treatment regimen ; patient Hodgkin Lymphoma must receive autologous stem cell transplant , refuse deem ineligible stem cell transplant ; Able understand willing sign inform consent form . Any histology Hodgkin Lymphoma , Mantle Cell Lymphoma Indolent Lymphoma ; History active Central Nervous System ( CNS ) malignancy ; Active graftversushost disease ( GVHD ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Lymphoid malignancy</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Indolent Lymphoma</keyword>
	<keyword>SB1518</keyword>
</DOC>